1030377-31-1

Basic information

• Product Name: Suvorexant intermediate
• Synonyms: Benzyl (5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepane-1-carboxylate
• CAS NO: 1030377-31-1
• Molecular Formula: C₂₄H₂₇N₅O₃
• Molecular Weight: 433.5
• EINECS: -0
• Mol File: 1030377-31-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Suvorexant intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: Suvorexant intermediate(1030377-31-1)
• EPA Substance Registry System: Suvorexant intermediate(1030377-31-1)

Safety Data

• Hazardous Substances Data: 1030377-31-1(Hazardous Substances Data)

Usage

General Description

Suvorexant intermediate, also known as 1-(4-Fluorophenyl)-1,3-dihydro-2H-benzo(d)imidazol-2-one, is a key chemical compound in the synthesis of the sleep medication suvorexant. It is a benzimidazole derivative that is used as a starting material for the production of suvorexant. This intermediate compound plays a crucial role in the pharmaceutical synthesis process, as it is an essential building block for creating the final drug product. Suvorexant is a potent and selective orexin receptor antagonist that is used for the treatment of insomnia. Therefore, the production of the suvorexant intermediate is a critical step in the manufacturing of this important pharmaceutical product.

Upstream product

• 956317-36-5 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoic acid 
• 1030377-25-3 1-benzyl 4-tert-butyl (5R)-5-methyl-1,4-diazepane-1,4-dicarboxylate 
• 501-53-1 benzyl chloroformate 
• 1638743-92-6 tert-butyl (R)-7-methyl-1,4-diazepane-1-carboxylate 

Relevant articles and documents

A facile electrochemical synthesis of suvorexant

A facile, scalable electrochemical method to prepare Suvorexant has been developed. Two different electrochemical routes explored. The route with the high yield and less step taken forward.

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.